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Making sense of propofol sedation for endoscopy  
 
Gastrointestinal endoscopy is one of the commonest hospital investigations and 
historically was associated with significant morbidity and mortality.1 The shortfalls in 
patient selection, sedation and monitoring identified by Quine and subsequent 
studies precipitated sustained interest in standards and training leading to the 
development of guidelines. Contemporary practice is dominated by midazolam-
opioid combinations used by non-anaesthetists and propofol with or without opioid or 
midazolam given by anaesthetists. 2 Non-anaesthetist propofol administration is 
constrained by regulatory considerations, guidelines and intense pressure from 
anaesthetists. Importantly, sedation practice is non-stationary with improvements in 
training, new equipment (processed EEG monitoring and capnography) and a 
developing literature describing emerging patterns of practice against a background 
of extreme cost pressure. Systematic audit of sedation practice and its outcomes is 
therefore essential as we refine our clinical teams and their pharmacological 
approaches. 
Leslie and colleagues3 documented 2,132 adult patients undergoing anaesthetist-
managed sedation at a group of hospitals in and around Melbourne, Australia. Their 
investigation comprises a well-structured prospective audit of events and outcomes 
in a patient population relevant to many international situations. Using intensive 
recruitment from multiple hospitals across a short period  a large cohort was swiftly 
recruited in just 28 days, a principle also demonstrated in an earlier snapshot 
sedation audit by anaesthesia trainees during a two-day period in six UK hospitals.2 
These procedures took place in well-appointed modern hospitals associated with a 
tertiary teaching centre. In addition to essential monitoring of arterial blood pressure, 
oxygen saturation and in most cases (64%) ECG, capnography was widely used 
(63.8%). Use of depth anaesthesia monitoring was minimal (0 .6%). 
Hypotension was common, with “significant hypotension” (systolic blood pressure 
<90 mm Hg and requiring intravenous fluid bolus or vasopressor) in 10.8% of 
elective cases and 16.4% of emergencies. Significant bradycardia (heart rate <55 
beats per minute and requiring a chronotropic agent) was less common (1.4 and 2.5% 
respectively). 
The study recruited only patients sedated by anaesthetists or supervised 
anaesthesia trainees and therefore, in some of the recruiting hospitals, a proportion 
of fitter patients who were triaged to (non-anaesthetist) operator sedation were 
excluded. This would affect the study population by reducing the number of fitter 
patients as a proportion of the total thereby exaggerating the fraction of less fit 
patients within the total requirement for sedation across the recruiting hospitals. 
What can we learn? Patients undergoing gastrointestinal endoscopy who received 
propofol sedation by anaesthetists experience a considerable number of adverse 
events, especially hypotension and some of them go on to die (overall mortality 1.2% 
at 30 days, 12.6% amongst those in ASA categories 4 and 5). Lower risk patients 
(ASA 1-2) fare better. 
Does the study tell us anything about the value of anaesthetists as sedationists? 
Since the investigation limited itself to sedation by anaesthetists there is no built-in 
control group of equivalent patients sedated by other professional groups.  
We can however look to the literature. In a large series of to 24,441 ASA 1-3 
endoscopy patients4 sedated  by endoscopist-directed nurses using propofol, the 
mean propofol doses for colonoscopy and gastroscopy were 150mg and 123mg 
respectively and lower than the median dose of 200mg given by Melbourne 
anaesthetists.3  In the same German series the patients co-administered midazolam 
received only 86mg or 82mg respectively for colonoscopy and gastroscopy 
respectively. This begs the question of why German nurse-sedationists use less 
propofol than Australian anaesthetists. If there is a cultural difference, is it because 
anaesthetists prefer to give more drug than nurses or is it something between 
Australia and Germany? Maybe Australian endoscopists want their patients to be 
“deeper”? A large series of 27,989 patients receiving endoscopist-directed nurse-
administered propofol sedation (EDNAPS) from another Australian centre reported a 
range of propofol doses (10-420mg) but did not report median/mean.5  
Recently, safe and effective nurse-administered deep sedation for advanced 
gastroenterological endoscopic procedures such as retrograde 
cholangiopancreatography and ultrasound has been reported with a mean propofol 
dose of 397mg used in 1899 patients over a five-year period.6 
We are left to reflect that sedation practice for endoscopy and access to propofol by 
non-anaesthetists is heterogenous7 and probably not evidence-based. It is certainly 
intensely political.8 UK guidance on sedation painstakingly avoids linking drugs to 
professional groupings preferring instead to recommend a competency-based 
approach.9 Earlier European guidance took a similar approach10 but was 
nevertheless rejected. 8 
What next? Leslie and colleagues recognise that their anaesthetists used generous 
propofol doses which are in turn associated with more hypotension (even if it is 
easily treated). Sensibly they acknowledge that the safety implications of this “high-
dose” propofol regimen are unclear. Two hypotheses emerge which are suitable for 
prospective testing in clinical trials. Firstly, the possibility that “high-dose” propofol 
sedation and its consequent induced hypotension might increase morbidity and 
possibly mortality. This can be tested by a randomised controlled trial of two different 
anaesthetist delivered propofol administration schemes (with by implication, two 
different depths of sedation) with additional endpoints for patient and operator 
satisfaction. Secondly, we can explore whether anaesthetist and non-anaesthetist 
propofol sedation may be equally safe, either in low-risk (ASA 1-2) or high-risk (ASA 
3-5 and more complex procedures). This could be tested by a randomised controlled 
trial of nurse versus anaesthetist sedation using a standardised (presumably low-
dose) propofol sedation scheme. A non-inferiority design with an appropriate effect 
size11 might be appropriate. Whether investigators can be found to push such 
studies past the politics and entrenched attitudes is another matter altogether… 
Finally, Leslie and colleagues remind us that propofol sedation, even when practised 
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